Literature DB >> 21079950

Bone metabolic activity in hyperostosis cranialis interna measured with 18F-fluoride PET.

Jérôme J Waterval1, Thijs M A Van Dongen, Robert J Stokroos, Jaap G J Teule, Gerrit J Kemerink, Boudewijn Brans, Fred H M Nieman, Johannes J Manni.   

Abstract

PURPOSE: (18)F-Fluoride PET/CT is a relatively undervalued diagnostic test to measure bone metabolism in bone diseases. Hyperostosis cranialis interna (HCI) is a (hereditary) bone disease characterised by endosteal hyperostosis and osteosclerosis of the skull and the skull base. Bone overgrowth causes entrapment and dysfunction of several cranial nerves. The aim of this study is to compare standardised uptake values (SUVs) at different sites in order to quantify bone metabolism in the affected anatomical regions in HCI patients.
METHODS: Nine affected family members, seven non-affected family members and nine non-HCI non-family members underwent (18)F-fluoride PET/CT scans. SUVs were systematically measured in the different regions of interest: frontal bone, sphenoid bone, petrous bone and clivus. Moreover, the average (18)F-fluoride uptake in the entire skull was measured by assessing the uptake in axial slides. Visual assessment of the PET scans of affected individuals was performed to discover the process of disturbed bone metabolism in HCI.
RESULTS: (18)F-Fluoride uptake is statistically significantly higher in the sphenoid bone and clivus regions of affected family members. Visual assessment of the scans of HCI patients is relevant in detecting disease severity and the pattern of disturbed bone metabolism throughout life.
CONCLUSION: (18)F-Fluoride PET/CT is useful in quantifying the metabolic activity in HCI and provides information about the process of disturbed bone metabolism in this specific disorder. Limitations are a narrow window between normal and pathological activity and the influence of age. This study emphasises that (18)F-fluoride PET/CT may also be a promising diagnostic tool for other metabolic bone disorders, even those with an indolent course.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079950      PMCID: PMC3070079          DOI: 10.1007/s00259-010-1655-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  21 in total

Review 1.  Age-related bone loss: old bone, new facts.

Authors:  George K Chan; Gustavo Duque
Journal:  Gerontology       Date:  2002 Mar-Apr       Impact factor: 5.140

2.  Fluorine-18: a new isotope for bone scanning.

Authors:  M BLAU; W NAGLER; M A BENDER
Journal:  J Nucl Med       Date:  1962-07       Impact factor: 10.057

3.  Assessment of porcine bone metabolism by dynamic.

Authors:  M Piert; T T Zittel; G A Becker; M Jahn; A Stahlschmidt; G Maier; H J Machulla; R Bares
Journal:  J Nucl Med       Date:  2001-07       Impact factor: 10.057

Review 4.  Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate.

Authors:  G M Blake; S J Park-Holohan; G J Cook; I Fogelman
Journal:  Semin Nucl Med       Date:  2001-01       Impact factor: 4.446

5.  18 F-fluoride for bone imaging.

Authors:  M Blau; R Ganatra; M A Bender
Journal:  Semin Nucl Med       Date:  1972-01       Impact factor: 4.446

6.  Phenotypic manifestations and management of hyperostosis cranialis interna, a hereditary bone dysplasia affecting the calvaria and the skull base.

Authors:  J J Waterval; R J Stokroos; N J C Bauer; R B J De Bondt; J J Manni
Journal:  Am J Med Genet A       Date:  2010-03       Impact factor: 2.802

7.  Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET.

Authors:  R A Hawkins; Y Choi; S C Huang; C K Hoh; M Dahlbom; C Schiepers; N Satyamurthy; J R Barrio; M E Phelps
Journal:  J Nucl Med       Date:  1992-05       Impact factor: 10.057

8.  The syndromic status of sclerosteosis and van Buchem disease.

Authors:  P Beighton; A Barnard; H Hamersma; A van der Wouden
Journal:  Clin Genet       Date:  1984-02       Impact factor: 4.438

9.  Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.

Authors:  Kenzo Uchida; Hideaki Nakajima; Tsuyoshi Miyazaki; Takafumi Yayama; Hideo Kawahara; Shigeru Kobayashi; Tatsuro Tsuchida; Hidehiko Okazawa; Yasuhisa Fujibayashi; Hisatoshi Baba
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

10.  Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry.

Authors:  C Messa; W G Goodman; C K Hoh; Y Choi; A R Nissenson; I B Salusky; M E Phelps; R A Hawkins
Journal:  J Clin Endocrinol Metab       Date:  1993-10       Impact factor: 5.958

View more
  4 in total

1.  NaF18-PET/CT Imaging of Secondary Hyperparathyroidism.

Authors:  Aung Zaw Win; Carina Mari Aparici
Journal:  Nucl Med Mol Imaging       Date:  2015-01-23

2.  Sodium 18F-fluoride PET/CT of bone, joint, and other disorders.

Authors:  Hossein Jadvar; Bhushan Desai; Peter S Conti
Journal:  Semin Nucl Med       Date:  2015-01       Impact factor: 4.446

3.  Conditional mouse models support the role of SLC39A14 (ZIP14) in Hyperostosis Cranialis Interna and in bone homeostasis.

Authors:  Gretl Hendrickx; Vere M Borra; Ellen Steenackers; Timur A Yorgan; Christophe Hermans; Eveline Boudin; Jérôme J Waterval; Ineke D C Jansen; Tolunay Beker Aydemir; Niels Kamerling; Geert J Behets; Christine Plumeyer; Patrick C D'Haese; Björn Busse; Vincent Everts; Martin Lammens; Geert Mortier; Robert J Cousins; Thorsten Schinke; Robert J Stokroos; Johannes J Manni; Wim Van Hul
Journal:  PLoS Genet       Date:  2018-04-05       Impact factor: 5.917

4.  Time course of bone metabolism at the residual ridge beneath dentures observed using ¹⁸F-fluoride positron emission computerized-tomography/computed tomography (PET/CT).

Authors:  Hanako Suenaga; Masayoshi Yokoyama; Keiichiro Yamaguchi; Keiichi Sasaki
Journal:  Ann Nucl Med       Date:  2012-08-18       Impact factor: 2.668

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.